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An ideal thrombolytic drug for use in treating acute myocar- 
dial infarction should be effective, safe and easy to admin- 
ister. The most widely used drug, streptokinase, has major 
side effects, including hypotension, and must be infused for 
at least 30 min (1). Furthermore, clot lysis is slower than 
with recombinant tissue-type lasminogen activator (&PA). 
The short half-life of r&PA necessitates a rather complicated 
dose regimen to achieve optimal efficacy (2). A novel recom- 
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plasminogen activator with a prolonged half-life (BM 
) has been developed (3). Experimental and preclinical 
data suggest that BM 06.022 isboth highly effective and easy 
to administer in the form of a short, single-dose bolus in- 
jection (4-6). 
Characteristics of the substance 
06.022 is a recombinant mutant of tissue-type plasminogen 
activator (t-PA) that is produced by expression i Esche- 
richiu co/i cells by means of genetic engineering (3). The 
active product is available after an in vitro refolding process. 
It contains only the Kringle-2 domain of t-PA and the 
protease domain and has no glycosidic side chains, which 
results in a prolonged half-life in Pnimals (6), healthy volun- 
teers (11.2 min) (7) and patients (19.2 min) (8). The apparent 
molecular weight is 40 kilodaltons and the specific activity 
-500 kU/mg. In vitro, r-PA has a low affinity for fibrin but is 
fibrin selective invivo. There is a lower affinity for endothe- 
lial c~:ils compared with rt-PA (3). 
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Patients with TM 2 or 3 
bolysis nMyocardial Infarction perfusion grade. 
. The first phase II trial with the drug was 
de open, sequential dose-finding study. The 
primary objective of the study was the early and reliable 
recognition f inadequately ffective doses of BM 06.022. To 
keep the number of patients reated by an inapprop 
as low as possible, a sequential design was chosen 
a sequential probability rate test o compare the null hypoth- 
esis of a 70% patency rate with an alternative 80% rate. We 
chose a1% alpha error and a 10% beta error. We stopped the 
test and concluded that he patency rate was 70% if the rate 
in our sample decreased sufficiently, as determined by the 
sequential probability ratio test. The cutoff points (lower 
boundary) are shown by the solid line in Fiiure 1. We did not 
consider using a corresponding upper boundary that would 
us to stop early and conclude that he patency 
If the sequentially plotted observed patency 
touched the lower boundary, the efficacy of the actual bolus 
dose was considered tobe unsatisfactory, and the dose was 
increased by 5 MU. If the observed patency remained above 
the lower boundary in 100 consecutive patients, then by 
definition this bolus dose was considered tobe efficacious, 
and no further dose was tested. 
Patency 90 min after the start of treatment, the main end 
point of the study, was reported immediately b telephone to
the coronary care unit of the Kassel Data and Evaluation 
Center, which was on call 24 h a day. Thus, continuous, 
sequential plotting of the individual patency data permitted 
very close monitoring of the study with respect o the 
primary study objective. 
The study protocol was approved by the Ethics Commit- 
tee of the University of Giittingen on July 19, 1990. 
R&eats. From October 1990 to March 1991, a total of 
I42 patients, 25 to 75 years old, presenting with an acute 
myaardial infarction -4 h i uration after the onset of 
chest pain, were enrolled. Th st 42 patients were treated 
with an open-label bolus of IO and the next 
with 15 MU of r-PA at 16 clinical centers. Inclu 
were symptoms and ST segment elevation typical of acute 
myocardial nfarction and have been detailed elsewhere ( 
Exclusion criteria were any of the recognized co~t~indica- 
tions to thrombolytic therapy, i~clMding blood pressure 
>200 mm IQ (systolic) or >l 
ous myocardial infarcti 
he last 6 months, left bu 
any other condition t 
bleeding during fibrin 
informed consent; p 
same area; previous fib~nolytic them 
After informer written or ve 
the presence ofa witness, the 
by telephone tothe cardiac are unit of the data center in 
study was documented and 
and the appropriate bolus of either IO 
06.022. Intravenous nitroglycerin was 
namically contraindicated. After admi 
medication, the patients were transfe 
tion laboratory. A coronary angiogram of the presumed 
ery was performed min after the bolus 
in at least wo ort onal views. Subse- 
quently, the other coronary arteries were filmed in standard 
projections. Another injection of contrast medium into the 
infarct-related artery was done at 60 min. At 98 min another 
angiogram of the infarct-related artery was obtained in the 
same projections as at 30 min. 
Whenever there was doubt about the location of the 
infarct-related site, a complete coronary angiogram was 
obtained at90 min. Thereafter, the investigators were free to 
perform additional recanalization procedures, but were 
askc Y to do so only in case of persistent myocardial ischemia 
or coronary occlusion (Thrombolysis in Myocardial Infarc- 
tion trial [TIMI] grade 0 or I perfusion) after the 98-min 
angiography. The femoral artery sheath was left in place, 
and another angiogram of the infarct-related artery was 
taken after 24 to 48 h. Before hospital discharge, another 
coronary and ventricular ngiogram was obtained whenever 
clinically indicated. Standard electrocardiograms were re- 
corded before and 4,8 and 24 h after treatment and before 
hospital discharge. Fibrinogen levels were determined be- 
fore and 2,4,8 and 24 h after treatment. 
Heparin was given intravenously immediately after the 
bolus of BM 06.022 at a rate of 1,008 U/h and adjusted 
according to an activated prot~r~mbi~ time of 1.5 to 2.5 
times normal for at least 48 h. In addition, 200 mg of 
acetylsalicylic acid was given daily throughout the study; the 
tirst dose was usually administered after completion ofthe 
first angiogram. 
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Diabetes (%) 
Hypertension (o/o) 
Heart faihre (%) 
Systolic blood pressure (mm Wg) 
iastolic blood pressure (mm Hg) 
eart rate (beatslmin) 
Anterior infarction (%) 
Time from symptom onset to 
were resolved by a 
median values and ranges: percents are used for proportions 
or success rates. 
After inclusion of 42 
initial ow dosage, the bolus of 10 
approached the lower preset limit of 
70%) in the Plot shown 
protocol, the bolus dos 
present maximal num 
treated without apgro 
. Baseline data revealed no appreciable dif- 
fe n groups Aand B (Table I). All patients who 
were enrolled received the study medication, except one 
patient in group A who showed spontaneous re o 
segment elevation and symptoms. One patient 
erroneously received 18 MU instead of 15 MU of 
He had no major clinical event and remained inthe 15-MU 
treatment group. 
ency rates of the infarct- 
related artery in groups A and are shown in Table 2. A 
30-min angiogram 32 group A and 61 group 
B patients, a 60-min angiogram in 41 group A and 99 group B 
patients and a 90-min angiogram in 42 group A and 99 group 
B patients. The patency rate according to the 90-min ’ 
gram was 66% in the IO- U group and 75% in the 1 
group. 
At 24 to 48 h, angiograms were available for 42 and 95 
patients and after 14 to 21 days for 38 and 85 patients in 
groups A and B, respectively. One patient in group B had no 
. Patency of hnfarcr- 
A~giogram at 30 min 32 62 
TM grade 2 or 3 21 (65) 41w 
TIMI grade 3 15 (46) 24 (38) 
Angiogram at 60 min 41 99 
TM grade 2 or 3 30 (73) 73 (74) 
TM grade 3 20 (48) 57 (58) 
Angiogram at 90 min 42 99 
TIMI grade 2 or 3 28 (66) 74 (75) 
TM grade 3 22 (52) 68 (69) 
Angagram at 24 to 48 h 42 95 
TM .grade 2 or 3 39 (92) 87 (92) 
TM grade 3 37 (88) 81 (85) 
Aogiog~am at 14 to 21 days 38 85 
TM grade 2 or 3 34 (89) 77 (9Q) 
TM grade 3 33 (86) 72 (85) 
Data presented are number (%) of patients. TlM = Thrombolysis in 
yocardial Infarction. 
in and no 24- to 
-min patency was near 
60-min patency, whereas it
(Tab!e 2). Very early reocclu 
1 perfusion i an artery that 
group A and in two patients ingroup B. A late reocchtsion 
between 24 to 48 h and predischa 
documented in two group A and three 
high patency rate >90% in the 24- to 
angiograms is confounded by interventions after the 90.min 
angiograplhy, including rescue angioplasty in 6 and 14 
tients with TM grade 0 or 1 perfusion i  groups A and 
respectively. 
Adverse vents, From treatment onset o the end of the 
first angiographic investigation, 10patients underwent defi- 
brillation, and 7 had temporary pacing for high grade atrio- 
ventricular block in both groups (Table 3). During the perio 
after the first angiogram and u to hospital discharge, four 
patients went into cardiogenic rot 
one in group A and four in group 
Eight patients had a reinfarction, e of whom was in group A. 
Bleeding complications were repo in a total of 35 
patients (9 in group A, 26 in group and were mostly 
hematomas or bleeding at puncture sites. In four patients 
hemorrhage was classified as a serious adverse vent: one 
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Group A Group B Total 
(n = 42) (n = IlW) (n = 142) 
Death in hospital 1 4 5 (3.5%) 
pu with nonfatal events 
Reinfarctioll I 7 8 (5.6%) 
Cardiogenic shock 1 3 5 (3.5%) 
VF 2 8 10 (7.0%) 
AV block II and/or Iii 4 6 10 (7.0%) 
Rs with bleeding 
Nonserious 9 25 34 (23.9%) 
serious I 3 4 (2.8%) 
&te presented are number (%I of patients (PM. AV = awioventricular; 
VF = ventricular fibrillation. 
nonfad cerebral hemorrhage (15 MU), one hemopericar- 
al hemorrhage (15 ) after 
rokinase and one injection site 
) (Table 3). Two of these patients 
Creatine kinase (CK) was measured 
dian peak value of 751 U/liter (range 
28 to 3,073) in group A and 801 U/liter (range 95 to 6,340) in 
group B was found 8 h after treatment. Median fibrinogen 
levels decreased from 2.79 g/liter (range 0.94 to 4.75) to 
I .69 g/liter (range 0.0 to 3.95) in group A and from 2.54 g/liter 
(range 0.0 to 5.02) to 0.92 g/liter (range 0.0 to 2.68) in group 
B 4 h after treatment. The median antigen concentration f 
BM 06.022 increased to157 @ml (range 29 to 339) in group 
A and 174 ng/ml (range 60 to 836) in group B 2 h after 
treatment, which corresponds to 50% of one plasma half-life. 
Hemoglobin content decreased from 15.1 to 12.7 g% in 
group A and from 14.7 to 12.5 g% in group B at 48 h after 
treatment. There were no significant changes in routine 
laboratory tests of blood cells and electrolyte, enzyme or CK 
levels other than those xpected during acute mywardial 
infarction. 
Antibodies toBM 06.022 were not detected inany patient 
at 1 month and S to 12 months after treatment, and several 
indicators of autoimmunogenic reactions, including antinu- 
clear antibodies determined in a subset of 20 patients, were 
also negative 5 to 12 months after treatment. 
A novel recombinant plasminogen activator has been 
developed that is significantly different from &PA in that it 
has a prolonged plasma half-life that allows a bolus injection 
instead of a complicated infusion regimen (9-11). From 
experimental nd preclinical investigations, the minimal 
Presumed effective dosage was calculated to be 10 MU. 
Therefore, in the present sequential dose-finding study, the 
first dose to be administered was a bolus of 10 MU of BM 
06.022. Inkeeping with the sequential design of the study, a 
Statistid decision could be made after 42 patients (27 
patients had a patent vessel) that he patency rate at 90 min 
was 570%. The probability hat this derision was false is 
10%. The dose was increased toa 15 
studied in an additional 
Study design. A spe 
to define patency limits 
be increased stepwise 
maximal number of patients t 
and “on-line” central data 
appropriate approach toke 
in acute diseases such as acute 
measure of efficacy (2,10) and was 
70%. 
related artery (TIM1 grade 0or l), accounting for actual or 
observed patency (naive stimator) of 66%. Patency at 30 
and 60 min was even higher, indicating very rapid thrombol- 
ysis with r-PA, which, however, was compromised byvery 
early reocclusion before the 90-min angiogram in 5 of 30 
arteries open at 30 or 60 min. This finding suggests a trend to 
early intermittent patency by incomplete thrombolysis or
rethrombosis, which has been a major problem with single 
bolus injections of the short-!ived mother compound rt-PA 
(14,15). A direct comparison with these studies, however, is
difficult, because to our knowledge onlp one study has 
systematically investigated the patency of the infarct-related 
artery at 30, 60 and 90 min, but very early reocclusion has 
not been mentioned (16). 
With the increased bolus dose of 15 MU, 60-min patency 
was in the same range as that achieved with the most 
effective &PA regimen (13). At 30 min after treatment, 66% 
of infarct-related arteries were found to be open. This 
finding, however, has to be regarded as potentially biased 
because only 62% of the patients had an angiogram at 
30 min. Nevertheless, 60min after the administration of the 
study drug, 99% of the patients had an 
patency rate was 74%. Adequate npe 
TIM1 grade 3 flow in the infarct-related artery, was seen in 
69% at 90-min angiography, which compares favorably with 
conventional thrombolytic herapy and is nearly identical to 
front-loaded &PA (13). 
i-in was gnen, as r 
treatment wer 
own was more pro- 
nounced in group B, indicating a progressive loss of fibrin 
specificity with high concentrations of r-PA after the larger 
bolus dose of 15 MU. 
The proportion ofpatients with a mi nogen level 
<I g/liter was significantly higher in gt % vs. 50%) 
and is in the same range as that after a bolus injection of 
50 mg of t-t-PA (15) or after anisoylated plasminogen strep 
tokinase activator complex (APSAC) (13). Whether these 
effects on fibrinogen breakdown translate into bleeding risk 
or may even improve the clinical outcome by lowering blood 
viscosity and thereby the reocclusion rate is still a matter of 
debzle. 
Other adverse events of special clinical interest, including 
ventricular fibrillation. atrioventricular block, cardiogenic 
shock, reinfarction a d a total of five deaths (Table 3), have 
been assessed and reviewed centrally. A trend toward a 
higher event rate in the 15-B&J group (31% vs. 24%) does not 
permit definite conclusions with regard to safety or optimal 
dosing. No indication was found to suggest that hese vents 
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